Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bao-Dong Qin

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
Primary pulmonary leiomyosarcoma: A population-based studyBao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang
Medical Hypotheses|June 3, 2018
Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapyBao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|September 19, 2012
[Recent progress in laboratory diagnosis of autoimmune liver disease]Ren-qian Zhong, Zai-xing Yang, Yan Liang, et al.
Frontiers in Pharmacology|March 3, 2025
Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinibJia-Jun Hui, Sheng-Jun Ding, Bao-Dong Qin, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data baseXiao-Dong Jiao, Bao-Dong Qin, Pu You, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2019
Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to CrizotinibBao-Dong Qin, Xiao-Dong Jiao, Ke Liu, et al.
Cancer Management and Research|March 23, 2018
Adenosquamous carcinoma of the bile duct: a population-based studyBao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapyBao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, et al.
Signal Transduction and Targeted Therapy|March 4, 2024
New clinical trial design in precision medicine: discovery, development and directionXiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, et al.
Oncology Research and Treatment|February 3, 2022
Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-AnalysisLing Peng, Bao-Dong Qin, Song Xu, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
Primary pulmonary leiomyosarcoma: A population-based studyBao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang
Medical Hypotheses|June 3, 2018
Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapyBao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|September 19, 2012
[Recent progress in laboratory diagnosis of autoimmune liver disease]Ren-qian Zhong, Zai-xing Yang, Yan Liang, et al.
Frontiers in Pharmacology|March 3, 2025
Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinibJia-Jun Hui, Sheng-Jun Ding, Bao-Dong Qin, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data baseXiao-Dong Jiao, Bao-Dong Qin, Pu You, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2019
Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to CrizotinibBao-Dong Qin, Xiao-Dong Jiao, Ke Liu, et al.
Cancer Management and Research|March 23, 2018
Adenosquamous carcinoma of the bile duct: a population-based studyBao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapyBao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, et al.
Signal Transduction and Targeted Therapy|March 4, 2024
New clinical trial design in precision medicine: discovery, development and directionXiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, et al.
Oncology Research and Treatment|February 3, 2022
Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-AnalysisLing Peng, Bao-Dong Qin, Song Xu, et al.
Pageof 5